Resveratrol Core-Shell Nanoparticles for Targeted Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of resveratrol (RSV) face challenges in enhancing bioavailability and targeted delivery to specific sites within the body, leading to inefficiencies in treating diseases such as Alzheimer's disease, atherosclerosis, cancer, chronic liver disease, Type 2 diabetes, heart disease, hypertension, and stroke.
Innovation Solution
Encapsulating resveratrol with a gum arabic shell and a polyvinyl alcohol coating to form nanoparticles with a size range of 195-210 nm and a PDI of 0.195-0.225, enhancing targeted delivery and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If resveratrol is administered in conventional formulations, then the basic therapeutic effect is achieved, but bioavailability is insufficient and targeted delivery is poor
Solution Approach 1:
The patent segments resveratrol into nanoparticle-sized particles (195-210 nm), which dramatically improves bioavailability and enables targeted delivery to specific tissues and cells, resolving the contradiction between basic therapeutic effect and efficient delivery
Solution Approach 2:
The patent employs a core-shell structure where resveratrol is encapsulated within a gum arabic shell, which is further coated with polyvinyl alcohol. This nested configuration protects the active ingredient while enhancing bioavailability and targeted delivery capability
2Reliability
If resveratrol is administered in conventional formulations, then the basic therapeutic effect is achieved, but side effects are not eliminated
Solution Approach 1:
The patent imparts local quality through targeted delivery of resveratrol nanoparticles to specific disease sites (e.g., tumor tissues, inflamed areas), concentrating the therapeutic effect where needed while minimizing systemic side effects through the selective accumulation of nanoparticles at target locations
3Ease of operation
If resveratrol is administered in conventional formulations, then the active component reaches the target site, but concentration is insufficient
Solution Approach 1:
The patent changes the physical parameters of resveratrol by formulating it as nanoparticles with controlled size (195-210 nm) and surface properties, which enables enhanced concentration at target sites through improved pharmacokinetics and active accumulation mechanisms while maintaining ease of administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The encapsulated RSV nanoparticles effectively increase Bcl-2 immunoreactivity, reduce apoptosis, and enhance CAR gene expression, providing therapeutic benefits for diseases of civilization.
Implementation Method 1
a gum arabic shell over the resveratrol core
Implementation Method 2
a polyvinyl alcohol coating over the gum arabic shell
Implementation Method 3
The encapsulated RSV nanoparticles effectively increase Bcl-2 immunoreactivity
Implementation Method 4
reduce apoptosis
Implementation Method 5
enhance CAR gene expression
Data Source
AI summary
Encapsulated resveratrol (RSV) nanoparticles having a resveratrol core, a gum arabic shell, and a polyvinyl alcohol coating over the gum arabic shell. In an embodiment, an RSV:gum arabic:polyvinyl alcohol (PVA) ratio in the encapsulated nanoparticles is about 1:5:5 (w/w/w). The encapsulated RSV nanoparticles can have an average size ranging from about 195 nm to about 210 nm.